Wednesday, July 8, 2026

Drug profile · INN

dezocine

dezocine (DALGAN) is a kappa opioid receptor antagonist. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — dezocine
US status
approved
Class
Route
INJECTION
Patents
0
Programs
0
Data quality
0.84

Quick answer

dezocine (DALGAN) is a kappa opioid receptor antagonist. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN dezocine
Brand DALGAN
Mechanism Kappa opioid receptor antagonist
Target Kappa-type opioid receptor
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Kappa opioid receptor antagonist

Primary target: Kappa-type opioid receptor

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. buprenorphine Nervous system (N07)
  2. buprenorphine hydrochloride Mu opioid receptor agonist
  3. anileridine hydrochloride Kappa opioid receptor agonist
  4. anileridine phosphate Kappa opioid receptor agonist
  5. butorphanol tartrate Kappa opioid receptor partial agonist
  6. difelikefalin acetate Kappa opioid receptor agonist

Frequently asked questions

What is dezocine?

dezocine (DALGAN) is a kappa opioid receptor antagonist. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for dezocine?

DALGAN is a marketed brand name for dezocine. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of dezocine?

dezocine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.